StockData
JNJNYSEPharmaceutical PreparationsFiscal year ends January 3

JOHNSON & JOHNSON

Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Oct 21, 2026
$253.79−1.77 (-0.69%)

Close on Oct 19, 2026

Market cap
$619.27B
P/E (TTM)
29.4
Dividend yield
2.03%

Earnings

Next report expected Oct 13, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 28, 2026
Jul 15, 2026Before market open–––
Q1 FY2026
Ended Mar 29, 2026
Apr 14, 2026Before market open$24.06B$2.14$2.70
Q4 FY2025
Ended Dec 28, 2025
Jan 21, 2026Before market open$24.60B$2.10$2.46
Q3 FY2025
Ended Sep 28, 2025
Oct 14, 2025Before market open$24.00B$2.12$2.80
Q2 FY2025
Ended Jun 29, 2025
Jul 16, 2025Before market open$23.74B$2.29$2.77
Q1 FY2025
Ended Mar 30, 2025
Apr 15, 2025Before market open$21.89B$4.54$2.77
Q4 FY2024
Ended Dec 29, 2024
Jan 22, 2025Before market open$22.50B$1.41$2.04
Q3 FY2024
Ended Sep 29, 2024
Oct 15, 2024Before market open$22.50B$1.11$2.42
Q2 FY2024
Ended Jun 30, 2024
Jul 17, 2024Before market open$22.40B$1.93$2.82
Q1 FY2024
Ended Mar 31, 2024
Apr 16, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Jan 23, 2024Before market open–––

Company guidance

Outlook given with results on Jul 15, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Operational Sales Change vs. Prior Yearnon-GAAPFull-year 20266.5% to 7.1% growthNew
Adjusted EPS (Diluted) Change vs. Prior Yearnon-GAAPFull-year 20267.5% to 8.9% growthRaised
Estimated Reported Sales Change vs. Prior Yearnon-GAAPFull-year 20267% to 7.6% growthRaised
Adjusted Operational EPS (Diluted) Change vs. Prior Yearnon-GAAPFull-year 20266.6% to 8% growthMaintained

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Johnson & Johnson filed with the SEC